Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Placebo Controlled Trial of 4-Hydroxytamoxifen Gel for Reducing Breast Tissue Density in Women With BI-RADS Breast Density Categories C or D

Trial Profile

A Randomized, Double-blind, Placebo Controlled Trial of 4-Hydroxytamoxifen Gel for Reducing Breast Tissue Density in Women With BI-RADS Breast Density Categories C or D

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 31 Jan 2019

At a glance

  • Drugs Afimoxifene (Primary)
  • Indications Hyperplasia
  • Focus Registrational; Therapeutic Use
  • Acronyms 4WARD
  • Sponsors BHR Pharma
  • Most Recent Events

    • 27 Jan 2019 The trial has been discontinued in Spain, according to European Clinical Trials Database.
    • 15 Jan 2019 Planned End Date changed from 30 Oct 2020 to 31 Mar 2019.
    • 15 Jan 2019 Planned primary completion date changed from 30 Oct 2019 to 31 Mar 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top